Chinese Hepatolgy ›› 2026, Vol. 31 ›› Issue (9): 1331-1334.

• Other Liver Diseases • Previous Articles     Next Articles

Treatment response and bile acid composition characteristics in late-onset intrahepatic cholestasis of pregnancy

Li Yuexin1, Qiu Ju1, Zhu Shasha2, Qian Jin1   

  1. 1. Department of Obstetrics and Gynecology, Rugao People's Hospital, Rugao 226500,China;
    2. Department of Laboratory Medicine, Rugao People's Hospital, Nantong 226500,China
  • Received:2026-01-18 Online:2026-09-30 Published:2026-11-16
  • Contact: Qian Jin, Email: 361741379@qq.com

Abstract: Objective To investigate the therapeutic response to different treatment regimens in patients with late-onset intrahepatic cholestasis of pregnancy (ICP) and to analyze the relationship between bile acid composition characteristics and treatment response. Methods A total of 94 pregnant women diagnosed with late-onset ICP from Rugao People's Hospital between March 2021 and December 2024 were enrolled. According to treatment regimens, patients were divided into a standard treatment group and a combination therapy group, and therapeutic outcomes were compared between the two groups. According to disease severity, patients were categorized into mild ICP and severe ICP groups, and differences in therapeutic efficacy and bile acid composition were analyzed. Patients were further classified into responders and non-responders based on treatment response, and bile acid profile characteristics were compared between these groups. Outcome measures included serum total bile acids (TBA), liver function parameters, improvement of clinical symptoms, and the proportions of bile acid components. Results After treatment, the TBA level in the combination therapy group was lower than that in the standard treatment group [(10.9±5.3) μmol/L vs. (15.8±6.7) μmol/L, P<0.05], with a greater reduction in TBA [(18.2±4.9) μmol/L vs. (12.6±3.0) μmol/L, P<0.05]. The pruritus relief rate (81.8% vs. 62.0%) and overall treatment response rate (77.3% vs. 54.0%) were both significantly higher (P<0.05). The mild ICP group showed a greater percentage reduction in TBA than the severe ICP group [(58.4±21.3)% vs. (37.4±17.2)%, P<0.05], lower post-treatment TBA levels [(11.6±5.8) μmol/L vs. (23.9±8.4) μmol/L, P<0.05], and a higher response rate (72.1% vs 46.2%, P<0.05). Regarding bile acid composition, the severe ICP group exhibited higher proportions of CA [(31.5±7.2)% vs. (24.1±6.3)%], CDCA [(41.2±8.5)% vs. (33.7±7.8)%], LCA [(6.8±2.7)% vs. (4.3±1.9)%], and proportion of conjugated bile acids [(72.4±11.2)% vs. (58.9±10.6)%], but a lower proportion of DCA [(15.4±4.8)% vs. (21.6±5.9)%] (all P<0.05). The non-responder group had higher baseline TBA levels than the responder group [(35.6±11.4) μmol/L vs. (23.7±8.9) μmol/L, P<0.05], with increased proportions of CA, CDCA, and LCA and a decreased proportion of DCA (all P<0.05). Conclusion Treatment response in patients with late-onset ICP is closely associated with treatment regimen, disease severity, and bile acid composition characteristics. Combination therapy can significantly improve clinical outcomes, while alterations in bile acid profiles may influence therapeutic response. Bile acid composition characteristics may serve as potential indicators for assessing disease status and predicting treatment response in late-onset ICP.

Key words: Intrahepatic cholestasis of pregnancy, Total bile acids, Bile acid profile